FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.
Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.
Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.
NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.
NIH Panel Calls for Further Research On End-of-Life Issues.
NAS Committee Urges Greater Rewards For Interdisciplinary Research.
CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.
Funding Opportunities Listed.
Trending Stories
- As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
